Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBr.small Co.2 Regulatory News (BSC)

Share Price Information for Br.small Co.2 (BSC)

Share Price is delayed by 15 minutes
Get Live Data
50.55    0.00 (0.00%)
Bid:
49.60
Ask:
51.50
Spread: 1.90 (3.831%)
Market Cap: £193.32m
BSC Live PriceLast checked at - London Stock Exchange

Intraday Br.small Co.2 Share Chart

Interim Management Statement

16 Nov 2009 13:19

RNS Number : 5697C
British SmallerTechCompaniesVCT2PLC
16 November 2009
 



BRITISH SMALLER TECHNOLOGY COMPANIES VCT 2 PLC ("the Company")

INTERIM MANAGEMENT STATEMENT

For the quarter ended 30 September 2009

British Smaller Technology Companies VCT 2 plc presents its interim management statement for the quarter ended 30 September 2009. This constitutes the Company's second interim management statement for the financial year ending 31 December 2009, as required by Rule 4.3 of the Disclosure and Transparency Rules. A copy of this interim management statement can be found at www.yfmgroup.co.uk.

The unaudited net asset value per Ordinary share as at 30 September 2009 was 73.0p (30 June 200975.7p). The net asset value as at 30 September 2009 is stated after taking account of the interim dividend of 2.0p per Ordinary share and the special dividend of 2.0p per Ordinary share in respect of the year ended 31 December 2009. These dividends were paid on 2 October 2009 and 30 October 2009 respectively.

The total return at 30 September 2009, calculated by reference to the net asset value per share and the cumulative dividends paid and proposed, increased to 95.0p per share from 93.7p at 30 June 2009.

The number of Ordinary shares in issue at 30 September 2009 was 16,641,257. There were no shares purchased or issued by the Company during the quarter.

Net assets at 30 September 2009 comprised the following:

£000

% of net assets

Unquoted investments at fair value

4,677

38.5%

Quoted investments at bid price

1,023

8.4%

Gilt investments

3,898

32.1%

Total investments

9,598

79.0%

Cash and cash equivalents

1,986

16.3%

Other net current assets (liabilities)

570

4.7%

Net assets

12,154

100.0%

The ten largest investments by valuation at 30 September 2009 were as follows:

£000

% of net assets

Digital Healthcare Limited

1,659

13.6%

Immunobiology Limited

807

6.6%

Primal Pictures Limited

742

6.1%

Pressure Technologies plc

440

3.6%

Silistix Limited

387

3.2%

Waterfall Services Limited

382

3.2%

Harvey Jones Limited

273

2.3%

Patsystems plc

258

2.1%

Ellfin Home Care Limited

150

1.2%

RMS Group Holdings Limited

146

1.2%

Top ten investments

5,244

43.1%

Other investments

456

3.8%

Gilt investments

3,898

32.1%

Total investments

9,598

79.0%

Quoted investments are carried at bid price at 30 September 2009. Unquoted investment are carried at fair value as at 30 September 2009 as determined by the directors.

During the three months ended 30 September 2009 the following significant investment transactions took place (all companies are unquoted except where otherwise indicated):

Disposals

Name of company:

Sale proceeds

£000

Original 

cost

£000

Carrying value at 

30 June 2009

£000

DxS 

1,755*

163

817

ART Technology Group (AiM)

567

244

519

Oxonica (AiM)

3

62

6

RMS Group Holdings 

3

3

3

2,328

472

1,345

* excluding deferred proceeds of £214,000

Performance 

In this period the Company has seen its underlying net asset value decrease by 2.7p per share after the payment of an interim dividend of 2.0p per Ordinary share and a special dividend of 2.0p per Ordinary share. 

The total return, calculated by reference to the net asset value plus cumulative dividend paid and proposed has increased by 1.3p to 95.0p per share, cumulative dividends representing 22.0p per share.

The net asset value currently comprises 48% in cash and gilts and as such the Company is well placed to take advantage of selective investment opportunities as they arise.

The net asset value per share remains significantly in excess of the current share price.

Outlook 

Whilst there remains uncertainty over the speed of recovery in the markets the last quarter has demonstrated that positive realisations are still possible for the right quality of investments. There is some evidence of an increasing search for capital from businesses seeking to expand which your Board believes will translate into increasing investment opportunities over both the short and medium term. This Company is well placed to continue to support these investments and take advantage of investment opportunities that may arise in the short term and is intending to ensure it has sufficient capacity to meet future investment demand. 

16 November 2009

For further information please contact:

David Hall  YFM Private Equity Tel: 0161 832 7603

Jeff Keating Singer Capital Markets Tel: 0203 205 7500

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IMSGUGMGGUPBGWQ
Date   Source Headline
4th Apr 20233:25 pmRNSDirector/PDMR Shareholding
4th Apr 20233:24 pmRNSDirector/PDMR Shareholding
4th Apr 20233:22 pmRNSIssue of Equity and Close of Offers
29th Mar 20238:40 amRNSTransaction in Own Shares
27th Mar 20236:00 pmRNSClose of Offers to new Applications
27th Mar 20236:00 pmRNSClose of Offers to new Applications
23rd Mar 202311:30 amRNSPublication of Circular
22nd Mar 202312:15 pmRNSPublication of Supplementary Prospectus
22nd Mar 202312:15 pmRNSPublication of Supplementary Prospectus
20th Mar 20233:00 pmRNSAnnual Financial Report
14th Feb 20234:35 pmRNSOffer Update
14th Feb 20234:35 pmRNSOffer Update
11th Jan 202310:00 amRNSPayment of Dividend and Issue of Equity
19th Dec 20228:50 amRNSTransaction in Own Shares
6th Dec 20229:58 amRNSOffer Update
6th Dec 20229:58 amRNSOffer Update
30th Nov 202212:30 pmRNSPublication of a Prospectus
30th Nov 202212:30 pmRNSPublication of a Prospectus
25th Nov 20229:30 amRNS3rd Quarter Results
4th Nov 20228:30 amRNSDividend Declaration
24th Oct 20229:00 amRNSChange of Registrar
3rd Oct 20221:30 pmRNSOffer Update
3rd Oct 20221:30 pmRNSOffer Update
3rd Oct 202212:24 pmRNSPayment of Dividend and Issue of Equity
28th Sep 202211:12 amRNSTransaction in Own Shares
20th Sep 20229:30 amRNSHalf-year Report
4th Aug 202211:45 amRNSDividend Declaration
2nd Aug 20221:15 pmRNSStatement re intention to fundraise
2nd Aug 20221:15 pmRNSStatement re intention to fundraise
29th Jun 202210:00 amRNSPurchase of Own Securities and Net Asset Value
21st Jun 20223:00 pmRNSInterim Management Statement
13th Jun 20223:51 pmRNSResult of AGM
6th May 20229:14 amRNSPayment of dividend and Issue of Equity
30th Mar 20228:00 amRNSTransaction in Own Shares
21st Mar 20221:15 pmRNSAnnual Financial Report
25th Feb 202212:03 pmRNSResult of General Meeting
31st Jan 202212:00 pmRNSPublication of Circular
7th Jan 202211:15 amRNSDirector/PDMR Shareholding
7th Jan 202211:15 amRNSIssue of Equity and Close of Offers
7th Jan 202211:15 amRNSDirector/PDMR Shareholding
7th Jan 202211:15 amRNSDirector/PDMR Shareholding
16th Dec 20219:57 amRNSTransaction in Own Shares
6th Dec 202110:37 amRNSPublication of Supplementary Prospectus
6th Dec 202110:33 amRNSPublication of Supplementary Prospectus
18th Nov 20218:08 amRNSInterim Management Statement
16th Nov 202110:06 amRNSPayment of dividend and allotment of shares
12th Nov 20217:00 amRNSClose of Offers to New Applications
12th Nov 20217:00 amRNSClose of Offers to New Applications
25th Oct 202112:08 pmRNSPayment of Dividend and Issue of Equity
19th Oct 202110:14 amRNSNet Asset Value and Dividend Re-investment Scheme

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.